Granted Patent B2

US 12,473,593 · App. 17/397,320 · Granted Nov 18, 2025

Inventors: Clive Gavin Brown (Cambridge, GB); Daniel John Turner (Oxford, GB); James White (Oxford, GB)

Assignee: Oxford Nanopore Technologies PLC

C12Q1/6869C12Q1/6883G01N27/4166C12Q2600/118C12Q2600/158C12Q2600/178

Abstract

Claims (24)

1 . A method of characterising a target ribonucleic acid (RNA), comprising:

(a) hybridising a primer to the target RNA and using the primer to form a complementary polynucleotide from the target RNA;

(b) contacting the complementary polynucleotide with a polynucleotide binding protein and a transmembrane pore such that the polynucleotide binding protein controls the movement of the complementary polynucleotide through the pore; and

(c) taking one or more measurements as the complementary polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the complementary polynucleotide and thereby characterising the target RNA,

wherein method does not comprise polymerase chain reaction (PCR) or reverse transcription PCR (RT-PCR), and

wherein the complementary polynucleotide is contacted with the pore when the complementary polynucleotide is fully or partially hybridized to the target RNA.

2 . The method according to claim 1 , wherein step (a) comprises forming a complementary deoxyribonucleic acid (cDNA) from the target RNA.

3 . The method according to claim 1 , wherein the primer comprises a leader sequence and/or a region to which a polynucleotide binding protein is capable of binding.

4 . The method according to claim 1 , wherein the target RNA is eukaryotic.

5 . The method according to claim 1 , wherein the target RNA comprises a polyA tail and step (a) comprises hybridising a primer to the polyA tail of the target RNA and using the primer to reverse transcribe the target RNA to form the complementary polynucleotide.

6 . The method according to claim 5 , wherein the primer is a polyT-VN primer, which comprises a polyT region and a VN anchor where V is dAMP, dCMP or dGMP and N is dAMP, dCMP, dGMP or dTMP.

7 . The method according to claim 1 , wherein the complementary polynucleotide is coupled to the membrane.

8 . The method according to claim 1 , wherein the one or more characteristics are selected from (i) the length of the target RNA, (ii) the identity of the target RNA, (iii) the sequence of the target RNA, and (iv) the amount of the target RNA.

9 . The method according to claim 1 , wherein the one or more characteristics of the complementary polynucleotide are measured by electrical measurement and/or optical measurement; optionally wherein the electrical measurement is a current measurement, an impedance measurement, a tunnelling measurement or a field effect transistor (FET) measurement.

10 . The method according to claim 1 , wherein the polynucleotide binding protein is a polymerase, exonuclease, helicase or a topoisomerase.

11 . The method according to claim 1 , wherein the pore is a transmembrane protein pore or a solid state pore.

12 . The method according to claim 11 , wherein the transmembrane protein pore is derived from a hemolysin, leukocidin, Mycobacterium smegmatis porin A (MspA), MspB, MspC, MspD, outer membrane porin F (OmpF), outer membrane porin G (OmpG), outer membrane phospholipase A, Neisseria autotransporter lipoprotein (NalP) or WZA.

13 . The method according to claim 12 , wherein the transmembrane protein is:

(a) formed of eight identical subunits as shown in SEQ ID NO: 2 or (b) a variant thereof in which one or more of the eight subunits has at least 50% homology to SEQ ID NO: 2 based on amino acid identity over the entire sequence and retains pore activity; or

(c) formed of seven identical subunits as shown in SEQ ID NO: 4 or (d) a variant thereof in which one or more of the seven subunits has at least 50% homology to SEQ ID NO: 4 based on amino acid identity over the entire sequence and retains pore activity.

14 . The method according to claim 1 , wherein the target RNA is messenger RNA (mRNA) or microRNA (miRNA).

15 . The method according to claim 14 , wherein the mRNA or miRNA can be used to diagnose or prognose a disease or condition.

16 . A method of determining whether or not a patient has or is at risk of developing a disease or condition associated with an altered amount and/or alternate splicing of messenger RNA (mRNA), comprising determining the amount and/or identity of the mRNA in a sample from the patient using the method according to claim 1 and thereby determining whether or not the patient has or is at risk of developing the disease or condition.

17 . A method of determining whether or not a patient has or is at risk of developing a disease or condition associated with a miRNA, comprising determining the presence or absence of the miRNA in a sample from the patient using the method according to claim 1 and thereby determining whether or not the patient has or is at risk of developing the disease or condition.

Assignments (2)

Priority Claims (1)

Continuity (3)

References Cited (182)